血小板源性生长因子受体
癌症研究
酪氨酸激酶
受体酪氨酸激酶
医学
癌症
生长因子受体
血管内皮生长因子
ROR1型
受体
生长因子
内科学
血管内皮生长因子受体
作者
Girolamo Ranieri,Maria Abbondanza Pantaleo,M. Piccinno,M. Roncetti,Maddalena Mutinati,Ilaria Marech,Rosa Patruno,Annalisa Rizzo,Raffaele Luigi Sciorsci
标识
DOI:10.1016/j.critrevonc.2013.05.009
摘要
Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI